Ivonescimab Injection Clinical Trials

3 actively recruiting trials across 2 locations

▲ +1 trial since June 2026

Pipeline

Phase 3: 2

Top Sponsors

Summit Therapeutics2
Guangdong Association of Clinical Trials1

Indications

Lung Cancer3
Cancer3
Non Small Cell Lung Cancer2
PD-L1 Positive, as Determined by a Validated Assay1
No Prior Systemic Therapy Received for the Advanced or Metastatic Disease1

Other1 trial

Efficacy and Safety of Ivonescimab Monotherapy as First-Line Treatment for PD-L1-Positive, Driver Gene-Negative, Locally Advanced or Metastatic NSCLC: A Multicenter, Prospective, Real-World Cohort Study

Chandler, Arizona1 trial

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Clinical Study Site

Phase 3

Phoenix, Arizona1 trial

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Banner University Medical Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.